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Abstract
Gaucher and Fabry diseases are the most prevalent sphingolipidoses. Chronic inflammation
is activated in those disorders, which could play a role in pathogenesis. Significant degrees
of amelioration occur in patients upon introduction of specific therapies; however, restora-
tion to complete health status is not always achieved. The idea of an adjunctive therapy that
targets inflammation may be a suitable option for patients. PPS is a mixture of semisynthetic
sulfated polyanions that have been shown to have anti-inflammatory effects in mucopoly-
saccharidosis type I and II patients and animal models of type I, IIIA and VI. We hypothe-
sized PPS could be a useful adjunctive therapy to inflammation for Gaucher and Fabry
diseases. The objective of this work is to analyze the in vitro effect of PPS on inflammatory
cytokines in cellular models of Gaucher and Fabry diseases, and to study its effect in
Gaucher disease associated in vitro bone alterations. Cultures of peripheral blood mononu-
clear cells from Fabry and Gaucher patients were exposed to PPS. The secretion of proin-
flammatory cytokines was significantly reduced. Peripheral blood cells exposed to PPS from
Gaucher patients revealed a reduced tendency to differentiate to osteoclasts. Osteoblasts
and osteocytes cell lines were incubated with an inhibitor of glucocerebrosidase, and condi-
tioned media was harvested in order to analyze if those cells secrete factors that induce
osteoclastogenesis. Conditioned media from this cell cultures exposed to PPS produced
lower numbers of osteoclasts. We could demonstrate PPS is an effective molecule to
reduce the production of proinflammatory cytokines in in vitro models of Fabry and Gaucher
diseases. Moreover, it was effective at ameliorating bone alterations of in vitro models of
Gaucher disease. These results serve as preclinical supportive data to start clinical trials in
human patients to analyze the effect of PPS as a potential adjunctive therapy for Fabry and
Gaucher diseases.
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Introduction
Lysosomal diseases are a group of more than 50 genetic disorders caused by pathogenic muta-
tions in genes associated to lysosomal proteins. Various lysosomal disorders are due to enzyme
deficiencies leading to specific substrate accumulation within lysosomes. Gaucher and Fabry
diseases are the most prevalent sphingolipidoses. Although the primary cell defect is
completely known the pathophysiology is not completely uncovered. When disease status ini-
tiates at the cellular level, with substrate accumulation as the primary defect, secondary
responses are triggered. These secondary effects are new, unique and may be independent of
the primary defect [1].
The concept of the existence of chronic stimulation of the immune system in lysosomal dis-
orders has been introduced more than 3 decades ago. Inflammation is a hallmark in many
lysosomal disorders, characterized by high levels of proinflammatory cytokines such as TNFα,
IL1β, IL6 [2]. These cytokines are secreted by innate immune cells when their toll-like recep-
tors or NOD-like receptors recognize molecular patterns associated to pathogens or danger
signals (DAMPs) [3]. There is evidence that accumulated lysosomal substrates could behave as
DAMPs [4,5,6]. Alternatively, cell or tissue stress produced in response to deposits could be
the source of endogenous molecules recognized as DAMPs.
Inflammation is a quick and acute natural response of the immune system activated upon
by the presence of a pathogen or stress signals. It is self-limiting once the trigger is no longer
present. On the other side, chronic inflammation is a disease state, and it is established if dan-
ger signals cannot be eliminated. Chronic inflammation is generally a silent and slow process
[7], and tissue pathogenesis is not evident until there is irreversible damage with clinical
sequelae. This situation could be the case in lysosomal disorders, where there is a continuous
accumulation of substrates [8].
Fabry disease is caused by pathogenic mutations in GLA gene causing enzymatic deficiency
of alpha-galactosidase A leading to accumulation of globotriaosylceramide (Gb3) and lyso-
Gb3 not limited to lysosomes but also in plasma membranes and caveolae of endothelial cells.
Clinical manifestations may appear in childhood, and affection of target organs, kidney, heart
and brain, occurs in 3rd-4th decades of life. It has been suggested that Gb3 accumulation dysre-
gulates endothelial NO synthase leading to increased oxidative stress and reactive oxygen spe-
cies (ROS) resulting in Fabry’s cardiovascular-renal disease. Production of high levels of
proinflammatory cytokines are observed in Fabry patients. This effect could be produced as a
result of exposure to high levels of Gb3 to TLR4 in immune cells [4].
Gaucher disease is an autosomal recessive disorder due to deficient activity of the lysosomal
enzyme glucocerebrosidase (GCase) produced by pathogenic mutations in GBA1 gene. This
deficiency leads to accumulation of glucosylceramide mainly in macrophages. The most com-
mon phenotype is type I GD (GD1) consisting of visceral, hematological and skeletal alter-
ations [9]. It was recently shown that the substrate glucosylceramide is an endogenous ligand
for the receptor Mincle present in innate immune cells. This interaction induced the produc-
tion of inflammatory cytokines such as TNFα and IL-1β [6]. Abnormal bone manifestations
are the most debilitating symptoms for Gaucher patients, despite available treatment. It is well
known that the skeletal system is affected by immune system, and inflammation may have a
negative impact in bone homeostasis targeting osteoclasts, osteoblasts and osteocytes. [10].
For these two sphingolipidoses, specific therapies such as enzyme replacement therapy
(ERT) have been introduced. Significant degrees of amelioration occur in patients; however,
restoration to complete health status is not always achieved [11]. This depends on different
aspects related to onset of disease in the patient, severity, onset of therapy, and secondary
responses. With respect to chronic inflammation little is known if there is a beneficial effect of
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ERT on this immune response because many studies have shown no changes in cytokines of
treated patients [4, 12]. For this reason, the idea of an adjunctive therapy that targets inflam-
mation may be a suitable option for patients.
In the last years, several works have been published in relation to cartilage and bone pathol-
ogy in mucopolysaccharidoses (MPS) where inflammation was shown to be a key factor in
pathogenesis [13]. A compound called pentosan polysulphate (PPS) was proposed as therapy
in MPS models [14] and showed marked improvements in clinical behavior in addition to a
reduction of glycosaminoglycans [15, 16]. Based on these beneficial effects, clinical trials were
undertaken and are ongoing in MPS patients [17].
PPS is a mixture of semisynthetic sulfated polyanions that is approved by the FDA as an
oral medication for the treatment of interstitial cystitis, an inflammatory-like disease [18]. The
mechanism of anti-inflammatory action of PPS is not clear, but there is a report showing it
decreases NFkB activation [19].
Given the positive effect of PPS to reduce inflammation in mucopolysaccharidosis type I
and II patients and animal models of type I, IIIA and VI, we hypothesized PPS could be a use-
ful adjunctive therapy to inflammation in other LSD, such as Gaucher and Fabry diseases. The
objective of this work is to analyze the in vitro effect of PPS on inflammatory cytokines in cel-
lular models of Gaucher and Fabry diseases, and to study its effect in Gaucher disease associ-
ated in vitro bone alterations.
Materials and methods
Ethics statement
This study was approved by the Ethical Committee of IBYME (Instituto de Biologı́a y Medi-
cina Experimental, CONICET, Argentina) according to provisions of the Declaration of Hel-
sinki in 1995. Human PBMCs were isolated from patients and healthy blood donors in
accordance with the guidelines provided by the ethical committee. The nature and purpose of
the study were explained to all volunteers and all patients gave their written informed consent
prior to participation in this study. In the case of minors/children written informed consent
was obtained from the next of kin, caretakers, or guardians.
PBMC isolation and culture
Peripheral blood samples from 20 Fabry (F) and 14 Gaucher (G) patients or healthy controls
were collected. In the case of Gaucher patients samples were obtained 24 h before ERT infu-
sion. For Fabry studies, 15 samples were obtained from treatment naïve patients. Blood was
taken by venipuncture in heparin as anticoagulant and immediately processed. Mononuclear
cells from whole blood (PBMC) were isolated by Ficoll Hypaque (Sigma, St Louis,MO, USA)
gradient separation.
For cytokine levels, chitotriosidase activity and indirect osteoclast differentiation measure-
ments Fabry and Gaucher cells (2x106 cells/ml) were cultured in the presence of 5 μg/ml of
PPS for 72 h and conditioned media (CM) was harvested.
For direct osteoclastogenesis assays, PBMC from Gaucher patients or healthy donors were
seeded at 5 × 105 cells/ml and cultured at 37˚C in 5% CO2 atmosphere in α-minimum essen-
tial medium (α-MEM) supplemented with 2 mM L-glutamine, 10% heat inactivated fetal
bovine serum (Gibco-BRL, Life technologies, Grand Island, NY), 100 U of penicillin per ml
and 100 μg of streptomycin per ml (complete media) and 30 ng/ml of recombinant human
macrophage colony stimulating factor (M-CSF) (R&D, Minneapolis, MN, USA) for 14 days
replacing the media every 72 h. To identify osteoclasts, cells were fixed in 4% paraformalde-
hyde and stained for tartrate resistant acid phosphatase (TRAP; Sigma Aldrich, St Louis, MO,
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USA). TRAP positive multinucleated (more than 3 nuclei) cells were defined as osteoclasts,
and the number was determined by microscopic counts on a whole well.
Generation of Fabry disease in vitro model
Macrophage differentiation was carried out as previously described [4]. Briefly, PBMC
obtained from healthy donors buffy coats were washed with sterile pyrogen-free saline, centri-
fuged at 100 g for 10 min, and resuspended in AIM-V medium. Fifty ×106 cells were seeded in
75 cm2 culture flasks and cultured for 1 h at 37˚C and 5% CO2. Non-adherent cells were
removed by washing twice with warm saline, and remaining cells were cultured in AIM-V for
6 days with the addition of 30 ng/ml recombinant human M-CSF (R&D Systems, Minneapolis,
MN, USA), to stimulate their differentiation to macrophages (MF). Obtained cells were gently
resuspended in AIM-V, seeded in 12-well culture plates (5×105 cells/ well) and cultured for 24
h in the presence of 20 μM Gb3 (Matreya, Pleasant Gap, PA, USA) and/or 200 μM 1-deoxyga-
lactonojirimycin (DGJ, Sigma). For dose response experiments, 24 h culture media was replen-
ished with fresh media containing Gb3, DGJ and 2, 5 or 10 μg/ml of PPS and 72 h followed by
harvesting of the supernatant. In the case of kinetics experiments, after the initial 24 h media
was replenished with fresh media containing Gb3, DGJ and 5 μg/ml of PPS and the superna-
tant was harvested 24, 48 or 72 h later.
Cell line cultures
The murine osteocyte cell line MLO-Y4 was cultured in α-minimum essential medium (α-
MEM media, Gibco-BRL, Life Technologies, Grand Island, NY) supplemented with 2.5% of
FBS, 2.5% of bovine calf serum (Gibco-BRL), 100 U of penicillin per ml and 100 μg/ml of strep-
tomycin, at 37˚C in a 5%CO2 atm for 72 h in the presence or absence of conduritol- β-epoxide
(CBE) 500 mM (Matreya) and 5 μg/ml of PPS and the conditioned media was harvested.
Murine osteoblasts cell line MC3T3 was cultured at 37˚C in 5% CO2 atm in α-MEM supple-
mented with 2 mM L-glutamine, 10% heat inactivated fetal bovine serum (Gibco-BRL, Life
Technologies, Grand Island, NY), 100 U of penicillin per ml and 100 μg of streptomycin per
ml, in the presence or absence of 5 μg/ml of PPS. For conditioned media preparation superna-
tants were harvested 72 h after PPS addition. For osteoblast activity assays media was supple-
mented with osteogenic supplements, 1 mM sodium glycerophosphate, 50 mM L ascorbate
and 10−8 M dexamethasone (all Sigma Aldrich), for 14 days with changes of medium and PPS
every 3–4 days.
Indirect osteoclastogenesis studies
For testing induction of osteoclast formation by the addition of CM from PBMC, THP-1 cells
were seeded at 5 × 105 cells/ml and cultured at 37˚C in 5% CO2 atmosphere in complete
media and 30 ng/ml of recombinant human M-CSF for 72 h. Non- adherent cells were washed
out and adherent cells were used for the osteoclast formation assays.
For CM derived from mice cells, bone marrow-derived monocytes from C57Bl/6 mice were
seeded at 5 × 105 cells/ml and cultured at 37˚C in 5% CO2 atm complete media supplemented
with 30 ng/ml of recombinant murine macrophage colony stimulating factor (M-CSF) (R&D,
Minneapolis, MN, USA) for 48 h. Non-adherent cells were washed out and adherent cells were
used for the osteoclast formation assays. For all the assays the adherent cells were cultured in
CM and complete medium in a 1:1 ratio supplemented with M-CSF for 7 days replacing the
media every 48 h.
To identify osteoclasts, cells were fixed in 4% paraformaldehyde and stained for tartrate
resistant acid phosphatase (TRAP; Sigma Aldrich, St Louis, MO, USA). TRAP positive
Pentosan polysulfate in models of lysosomal storage disorders
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multinucleated (more than 3 nuclei) cells were defined as osteoclasts, and the number was
determined by microscopic counts on a whole well.
CHIT activity determination
CHIT activity was assessed in DBS (dried blood spot) and supernatant as follows: 3mm
diameter circle from DBS filter paper or 20 μl supernatant was placed into a well of a black
microplate and 40 μl of 0.25M sodium acetate buffer pH = 5.5 and 40 μl of 0.19 mM 4-meti-
lumbeliferil β-D-N-N0-N@- triacetylchitotrioside (Sigma) were added. After an incubation for
30 min at 37˚C, the stop solution (220 μl of 0.1 mol/l ethylenediamine, pH = 11.4) was added.
The fluorescence of the product (excitation 365 nm; emission 450 nm)was measured on a
Twinkle LB 970 fluorometer (Berthold Technologies, BadWild-bad, Germany). A standard
curve of 4-methylumbelliferone (Sigma, Saint Louis, MO, USA) was used to extrapolate fluo-
rescence counts to moles of enzymatic product. Enzymatic activity was expressed as micro-
moles of 4-methylumbelliferone produced per liter per hour.
Cytokine measurement
Cytokine levels in the supernatant fraction were quantified by capture ELISA (BD Biosciences)
following the manufacturer instructions.
Glycolipid measurement
Plasma globotriaosylsphingosine (lyso-GB3) was measured by liquid chromatography tandem
mass spectrometry (LC-MS/MS) using a published method with minor modifications [20].
Dimethyl psychosine was used as internal standard. Acquity UPLC BEH C18 column (2.1 mm
X 50 mm with 1.7 μm particle size) was used for chromatography. Plasma glucosylsphingosine
(lyso-GL1) was measured by a published LC-MS/MS method with minor modifications [21].
D5-glucosylsphingosine was used as internal standard. Lyso-GL1 is separated from its isomer
galactosylsphingosine (psychosine) using Acquity UPLC BEH amide column (2.1 mm X 100
mm with 1.7 μm particle size). Agilent 6490 triple quadruple mass spectrometer coupled with
Agilent 1290 liquid chromatography system was used for both analyses. Measurements were
performed in cell pellets and culture supernatants as indicated in each figure.
Quantification of mineralization by Alizarin Red S (ARS)
Monolayers in 6-well plates (10 cm2/well) were washed with PBS and fixed in 10% (v/v) form-
aldehyde (Sigma–Aldrich) at room temperature for 15 min. The monolayers were then washed
twice with excess dH2O prior to addition of 1 mL of 40 mM ARS (pH 4.1) per well. The plates
were incubated at room temperature for 20 min with gentle shaking. After aspiration of the
unincorporated dye, the wells were washed four times with 4 mL dH2O while shaking for 5
min. 800 μL 10% (v/v) of acetic acid was added to each well, and the plate was incubated at
room temperature for 30 min with shaking. The monolayer, now loosely attached to the plate,
was then scraped from the plate with a cell scraper (Fisher Life Sciences) and transferred with
10% (v/v) acetic acid to a 1.5-mL microcentrifuge tube. After vortexing for 30 s, the slurry was
overlaid with 500 μL mineral oil (Sigma-Aldrich), heated to exactly 85˚C for 10 min, and trans-
ferred to ice for 5 min. The slurry was then centrifuged at 20,000 g for 15 min and 500 μL of
the supernatant was removed to a new1.5-mL microcentrifuge tube. Then 200 μL of 10% (v/v)
ammonium hydroxide was added to neutralize the acid. In some cases, the pH was measured
at this point to ensure that it was between 4.1 and 4.5. Aliquots (150 μL) of the supernatant
were read in triplicate at 405 nm.
Pentosan polysulfate in models of lysosomal storage disorders
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Sirius Red
Osteoblasts cultured on 24 well culture plates were washed 3 times with PBS and fixed using
250 μl of Bouin fluid for 1 h. Bouin fluid was freshly prepared prior to use by mixing 15 ml of
saturated picric acid with 5 ml of formaldehyde 35% v/v. After fixation, cells were washed 3
times with excess of distilled water and allowed to dry for several minutes. 1 ml of a 0.1% Sirius
Red (Sigma-Aldrich) in picric acid solution was added and incubated at room temperature for
18 h with gentle shaking. After the incubation, cells were washed 5 times with 0.01 N HCl to
remove excess dye. For quantification 200 μl of 0.1 N NaOH were added and incubated for 30
min with shaking to dissolve the dye and the solution absorbance was measured at 550 nm.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 5.0 program applying t-test. Data
are presented as mean±SD. Experiments involving cells lines were carried out with an n = 5
and performed 3 independent times.
Results
Effect of PPS on cytokine production by Fabry macrophages in vitro
chemical model
Previously, we were able to reproduce the production of proinflammatory cytokines in Fabry
disease by the use of an in vitro chemical model of macrophages treated with Gb3 and DGJ [4].
We decided to use this model to check the proof of concept that PPS is able to inhibit cytokine
secretion in Fabry disease. A dose-response assay was carried out with concentrations of 2, 5
and 10 μg/ml of PPS in order to test efficacy and minimum effective dose. Addition of PPS to
this cell model significantly reduced the production of IL-1β and TNFα to control levels. As
can be seen in Fig 1A, the dose of 5 μg/ml is the minimum dose responsible for this effect.
To evaluate the best incubation time for PPS treatment we carried out a kinetics assay. Mac-
rophages were cultured in the presence of Gb3 and DGJ as previously and a dose of 5 μg/ml of
PPS for 24, 48 and 72 hours. As seen in Fig 1B, a reduction in TNF-α and IL-1β was observed
from 24 h of treatment achieving the highest differences in the 72 h time point. Based on these
results we chose the 5 μg/ml dose for 72 h of PPS treatment for the remainder of the experi-
ments performed.
Cytokine determination in culture supernatants from Fabry patients
Having demonstrated a positive effect of PPS in the chemical model, we decided to analyze the
response in mononuclear cells from Fabry patient’s. A significant reduction in the secretion of
cytokines IL-1β, TNFα, IL-6, IL-4 and IL-10 was revealed when PBMC from Fabry patients
were incubated with PPS (Fig 2A).
In order to discriminate if the effect of PPS was due to its well-known anti-inflammatory
properties or an unknown effect on glycolipid deposits we measured LysoGb3 levels in cell
homogenates and supernatants, with and without PPS. As can be seen in Fig 2B, PPS treatment
did not change LysoGb3 levels.
Cytokine and chitotriosidase determination in culture supernatants from
Gaucher patients
Given the positive effect observed in Fabry disease cultures, we tested the effectiveness on
another sphingolipidosis, Gaucher disease. PBMC from Gaucher patients treated with PPS
Pentosan polysulfate in models of lysosomal storage disorders
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secrete significantly less quantities of IL-1β, TNFα and IL-4 (Fig 3A). In Gaucher disease, the
biomarker chitotriosidase correlates with clinical severity and it is a good marker for follow-up
of ERT. For this reason we decided to measure this biomarker. No difference was observed in
chitotriosidase measurement from PBMC treated with PPS as compared to non-treated cul-
tures (Fig 3B).
As above, we assayed levels of LysoGL1 in Gaucher patients cells with or without PPS treat-
ment. No differences in LysoGL1 were detected because of PPS treatment (Fig 3C).
Fig 1. Fabry macrophages model with Gb3/DGJ: dose response (A) and kinetics (B). Based on this study, 5 μg/ml is the minimum dose responsible for cytokine
reduction. Data is shown as the mean±SD with n = 5 one representative experiment of 3 performed. �p<0,05 ��p<0,01 ���p<0,001 t-test.
https://doi.org/10.1371/journal.pone.0217780.g001
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Osteoclastogenesis studies
In the era of ERT, the skeletal manifestations represent the main obstacles for Gaucher patients
[22]. It is well recognized that an inflammatory environment alters bone homeostasis [23]. Stud-
ies have suggested an imbalance in bone homeostasis in GD where osteoclastogenesis and bone
resorption would be increased and bone formation would be reduced [24,25]. Both processes
could be triggered by high levels of proinflammatory cytokines in the bone microenvironment.
For this reason we questioned if PPS could have a beneficial effects on bone homeostasis.
In a previous work we have shown that PBMC from Gaucher patients have higher tendency
to differentiate into functional osteoclasts as compared to normal controls when cultured with
M-CSF [12]. We performed the same experiments in the presence of PPS. A significant reduc-
tion in osteoclast differentiation was observed for GD patient samples while no difference was
present in healthy control samples (Fig 4A). We also showed that THP-1 derived osteoclast pre-
cursors cultured in the presence of CM from PBMC of GD patients had higher differentiation
to active osteoclasts and that this effect was mediated, at least in part, by TNF-α. As showed in
Fig 3A PPS reduced TNF-α release from PBMC of GD patients therefore we decided to test if
PPS had an effect on osteoclastogenesis. We cultured PBMC from GD patients and healthy con-
trols in the presence of PPS for 72 h and harvested the CM. The CM was used in osteoclast dif-
ferentiation assays using THP-1 derived osteoclast precursors. Conditioned media from PPS
treated GD PBMC induced significantly less osteoclast differentiation that CM from untreated
cells, while no difference was observed when control PBMC were used (Fig 4B).
Osteocytes are long-lived cells that derive from osteoblasts. Both cell types constitute a
source of RANKL, the main inducer of bone resorption [26]. In a previous work we showed
that CM from CBE treated osteocytes induced higher osteoclast differentiation that control
CM [25]. In the present work we questioned if PPS could reduce this effect. Therefore, we cul-
tured MLO-Y4 cells (an osteocyte cell line) and MC3T3 cells (an osteoblast cell line) in the
presence of CBE and/or PPS for 72h and conditioned media were harvested. The CM was used
for osteoclast differentiation using osteoclast precursors derived from bone marrow precur-
sors. As shown in Fig 4C CM from CBE treated osteocytes and osteoblasts generated higher
osteoclastogenesis that control CM while PPS treatment reduced this effect to control levels.
Bone formation by osteoblasts
The other side playing a role in bone homeostasis is bone formation mediated by osteoblasts.
It has been proposed that osteoblast activity is reduced in GD [27]. To evaluate this effect,
active osteoblasts were obtained from MC3T3 cells in the presence of CBE. CBE treatment
reduced collagen deposition as well as mineralization (Fig 5A and 5B). Next we tested if PPS
had any effect on these parameters. Osteoblasts were cultured in the presence of CBE and/or
PPS. Mineral deposition was increased in PPS treated osteoblasts both in control and CBE cul-
tures (Fig 5B), however surprisingly collagen deposition was reduced in the presence of PPS
(Fig 5A).
Discussion
Recent discoveries and developments in the field of lysosomal disorders have pointed our
attention to physiopathological processes underlying these pathologies. Accumulation of
Fig 2. Cytokine determination in culture supernatants from naïve Fabry patients (F) and healthy controls (Ctl), in the presence or not
of PPS (2A). Lyso Gb3 levels in cell homogenates and culture supernatants (2B) from naïve Fabry patients and controls with or without
PPS. Data is shown as the mean±SD. �p<0,05 t-test.
https://doi.org/10.1371/journal.pone.0217780.g002
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deposits is simply and uniquely the first cell manifestation of damage, and is only one piece of
the resultant pathogenesis in these diseases. This initial manifestation triggers the firing of
multiple cascades of cellular mechanisms, being inflammation one of the most common and
Fig 3. Cytokine (3A) and chitotriosidase (3B) determination in culture supernatants from Gaucher patients (G) or healthy donors (Ctl), in
the presence or not of PPS. Lyso GL1 levels in cell homogenates and culture supernatants (3C) from Gaucher patients and controls with or
without PPS. Data is shown as the mean±SD. �p<0,05 ��p<0,01 t-test.
https://doi.org/10.1371/journal.pone.0217780.g003
Fig 4. Direct osteoclastogenesis from PBMC (A). Indirect osteoclastogenesis mediated by PBMC supernatant (B), osteoblasts and osteocytes (C). Data is
shown as the mean±SD with n = 5 one representative experiment of 3 performed. ��p<0,01 ���p<0,001 t-test.
https://doi.org/10.1371/journal.pone.0217780.g004
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almost universal in lysosomal disorders. Chronic inflammation plays a critical role in tissue
and organ malfunctioning [8].
Introduction of ERT was a revolution in the field and made a transformation for lives of
patients afflicted with lysosomal disorders. However, existing ERT have proven incomplete
correction of clinical affection [1]. Indeed, there is inconclusive evidence about the effect of
ERT on inflammation. For this reason, adjuvant therapies directed to target inflammatory
aspects appear as a rational option for treatment. In this regard, various studies have been car-
ried out to prove that PPS is a useful treatment for different types of MPS, by its effect as an
anti-inflammatory agent [15,17]).
Based on the knowledge that inflammation is a common pathological mechanism in lyso-
somal disorders together with the demonstrated anti-inflammatory effect of PPS in MPS we
hypothesized PPS could be useful at reducing inflammation in other lysosomal disorders, such
as Fabry and Gaucher.
There is no definitive conclusion as to whether ERT for Fabry disease modulates the
immune system to reduce the level of inflammation. Some studies showed no statistical differ-
ences in the expression or the production of cytokines when comparing between naive patients
or those undergoing ERT [4,28]. While other reports showed alterations of cytokine levels in
patients on ERT. In this ambiguous context it may be valuable to find a compound able to
reduce inflammatory components, as a possible way to improve/control the impact in target
organs [29]. In this study, we were able to show that PPS reduces the secretion of TNFα and
IL1β in a chemical in vitro model of Fabry disease to control levels. Moreover the same effect
was seen in PBMC from Fabry patients. One of the main clinical symptoms in Fabry is the
chronic and progressive nephropathy. This nephropathy has similarities to diabetic nephropa-
thy (DN) [30]. In a recent model of DN TNFα was shown to contribute to the inflammatory
lesions. PPS treatment in this model prevents the progression of nephropathy by decreasing
Fig 5. Bone formation activity as determined by collagen (A) and mineral deposition (B) by osteoblasts. Data is shown as the mean±SD with n = 5 one
representative experiment of 3 performed. �p<0,05 ��p<0,01 ���p<0,001 t-test.
https://doi.org/10.1371/journal.pone.0217780.g005
Pentosan polysulfate in models of lysosomal storage disorders
PLOS ONE | https://doi.org/10.1371/journal.pone.0217780 May 31, 2019 12 / 16
albuminuria, renal macrophage infiltration and TNFα expression; along to improvement of
histopathologic changes and renal function [31]. The heart is another main target organ in
Fabry and PPS has been shown to improve cardiac function in different animal models
[32,33]. One could speculate that PPS could have an effect in Fabry nephropathy and cardio-
miopathy, and in vivo studies would be necessary to analyze this hypothesis.
Previous studies in Gaucher disease revealed Gaucher patients undergoing ERT display a
proinflammatory profile, as demonstrated by increased production of proinflammatory cyto-
kines by peripheral blood T cells and monocytes [12]. By the present work, we are able to
affirm PPS, at least in vitro, has the capacity to reduce the secretion of those cytokines pro-
duced by PBMC.
In Gaucher disease skeletal problems are common and cause a high morbidity. As in other
inflammatory syndromes, bone homeostasis is affected. The inflammatory condition induces
higher bone resorption by osteoclasts and reduced bone formation by osteoblasts, resulting in
low bone density [10]. It seems reasonable to think that a compound that reduces inflamma-
tion may have a positive impact in bone affection. For this reason we analyzed the use of PPS
in in vitro bone models of Gaucher disease. In this study we detected that along with reduction
of production of proinflammatory cytokines by PBMC, PPS was capable to reduce the ten-
dency of osteoclast precursors to differentiate into active osteoclasts. In a recent article, it was
demonstrated the molecular mechanism by which PPS inhibits osteoclastogenesis [34]. More-
over, when Gaucher models of PBMC, osteoblasts and osteocytes are exposed to PPS, their
supernatant does not induce osteoclastogenesis implying that PPS downregulates the levels of
pro-osteoclastogenic factors resulting in less of bone resorption. On the other hand, chitotrio-
sidase has not changed with PPS treatment. It could be due to the reduced time of exposure of
PPS of 3 days in the culture. Future experiments in animal models and/or human patients
with longer exposure to PPS would elucidate if it has an effect.
Recently, PPS has been studied as a treatment for pain and lesions associated in osteoarthri-
tis, a condition that also has an inflammatory profile [35]. The positive result in a bone inflam-
matory condition together with our results in the in vitro bone Gaucher disease model make
PPS a potential drug to ameliorate skeletal problems in GD.
In order to discriminate if the effect of PPS was because of its well-known anti-inflamma-
tory effect or because a yet unknown effect on glycolipid deposits we determined the levels of
specific glycolipids for Fabry and Gaucher in cell homogenates and supernatants, with and
without PPS. Incubation of cells with PPS for 3 days did not produce changes in glycolipids
levels. By this work, we could rule out an effect of PPS on levels of deposits. It could also be
possible that 3 days of incubation is a short time to view a change. Longer exposure to PPS on
in vivo treatment could lead to reduction of glycolipids, like it was observed for GAGs reduc-
tion in MPS rat model [15]. Therefore the reduction of cytokine levels observed was not
because reduction of deposits but because PPS acts directly as anti-inflammatory agent. In this
context we could affirm PPS has a different mode of action independent of the one of specific
therapies which its targets are glycolipids.
Importantly, our work confirms that PPS is effective not only in lysosomal disorders associ-
ated to GAGs accumulation but also for the ones with glycolipid deposits. It may possibly
imply PPS could also be effective in lysosomal disorders associated to other accumulated
substrates.
In conclusion, PPS is an effective molecule to reduce the production of proinflammatory
cytokines in in vitro models of Fabry and Gaucher diseases. Moreover, it was effective at ame-
liorating bone alterations of in vitro models of Gaucher disease. This results serves as preclini-
cal supportive data to start clinical trials in human patients to analyze the effect of PPS as a
potential adjunctive therapy for Fabry and Gaucher diseases.
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